Document Detail

Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity.
MedLine Citation:
PMID:  21439785     Owner:  NLM     Status:  Publisher    
The purpose of the study was to examine the potential of inhibition of cathepsin S as a treatment for autoimmune diseases. A highly selective cathepsin S inhibitor, CSI-75, was shown to upregulate levels of the cathepsin S substrate, invariant chain Lip10, in vitro as well as in vivo in C57Bl/6 mice after oral administration. Functional activity of the compound was shown by a reduction in the OVA-specific response of OVA-sensitized splenocytes from C57Bl/6 mice as well as from OVA-TCR transgenic mice (DO11.10). Since these studies revealed a selective suppression of the Th1 and Th17 cytokines causing a shift to Th2, CSI-75 was tested in the murine HC-gp39-immunization model. Indeed, CSI-75 specifically reduced the circulating HC-gp39-specific IgG2a in these mice indicating selective inhibition of the Th1 type of response in vivo. The importance of especially the Th1 and Th17 cell subsets in the pathology of autoimmune diseases, renders CatS inhibition a highly interesting potential therapeutic treatment of autoimmune diseases. Therefore, CSI-75 was tested in a murine model of multiple sclerosis (i.e. experimental autoimmune encephalomyelitis (EAE)) in a semi-therapeutic setting (ie. oral treatment after initial sensitization to antigen). Finally, in a murine model with features resembling rheumatoid arthritis (the collagen-induced arthritis (CIA) model), CSI-75 was tested in a therapeutic manner (after disease development). CSI-75 caused a significant reduction in disease score in both disease models, indicating a promising role for CatS inhibitors in the area of therapeutic treatments for autoimmune diseases.
Mark Baugh; Darcey Black; Paul Westwood; Emma Kinghorn; Kieran McGregor; John Bruin; William Hamilton; Maureen Dempster; Christopher Claxton; Jiaqiang Cai; Jonathan Bennett; Clive Long; Heather McKinnon; Paul Vink; Leontien den Hoed; Monika Gorecka; Kalpit Vora; Ethan Grant; M David Percival; A Mieke H Boots; Marie-José van Lierop
Related Documents :
23666415 - Fgf23 and klotho in chronic kidney disease.
24689815 - Exposure to borrelia burgdorferi and other tick-borne pathogens in gettysburg national ...
15646765 - Leprosy: a case series and review.
21206715 - Kimura's disease: an uncommon cause of lymphadenopathy.
2918305 - The ratio of acetylcholinesterase to butyrylcholinesterase influences the specificity o...
6895415 - Treatment of stage i and ii mediastinal hodgkin disease. a comparison of involved field...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-3-23
Journal Detail:
Title:  Journal of autoimmunity     Volume:  -     ISSN:  1095-9157     ISO Abbreviation:  -     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-3-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8812164     Medline TA:  J Autoimmun     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011. Published by Elsevier Ltd.
MSD, Newhouse Industrial Estate, Newhouse, Motherwell ML1 5SH, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Outcomes assessment in the SPRINT multicenter tibial fracture trial: Adjudication committee size has...
Next Document:  Nucleic acid-stimulated antigen-presenting cells trigger T cells to induce disease in a rat transfer...